Posted by Michael Wonder on 07 Feb 2024
FDA grants latozinemab breakthrough therapy designation for frontotemporal dementia due to a progranulin gene mutation
7 February 2024 - Latozinemab is the most advanced progranulin-elevating candidate in development for frontotemporal dementia with a progranulin gene mutation and has now become the first investigational medicine to receive a breakthrough therapy designation for the treatment of frontotemporal dementia with a progranulin gene mutation.
Alector and GSK today announced that the US FDA has granted breakthrough therapy designation to latozinemab, an investigational human monoclonal antibody designed to block sortilin to elevate progranulin levels for the potential treatment of frontotemporal dementia with a progranulin gene mutation.
